December 13, 2021 -- Accellix has raised $10 million from BroadOak Capital Partners. Accellix is a biotechnology company that provides flow cytometry results in a compact, easy-to-use platform for use by cell therapy companies on the manufacturing floor and at the point of need.
BroadOak provides flexible growth capital and mergers and acquisitions advice for companies in the life sciences industry that provide tools and services. The investment is part of BroadOak's fifth fund and marks the firm's third investment in the last six months in the rapidly growing market of tools and services for cell and gene therapy development and manufacturing. BroadOak previously invested in Accellix as part of a prior fund.
Promising cell therapies continue to progress to the late stages of clinical development and into commercial products, increasing the need for routine and streamlined quality control (QC) process management. Accellix's products streamline a complex but necessary part of cell analysis, providing more robust outcomes and reducing overall QC costs in cell therapy manufacturing.